This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 May 5;29(5):777-778.

doi: 10.1093/eurjpc/zwab178.

Statins and lipoprotein(a); facing the residual risk

Gal Tsaban^{1

2}

Affiliations

Affiliations

¹ Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.
² Department of Cardiology, Heart Institute, Rager Av. 101, Beersheba, 84101, Israel.

PMID: 34904162
DOI: 10.1093/eurjpc/zwab178

Editorial

Statins and lipoprotein(a); facing the residual risk

Gal Tsaban. Eur J Prev Cardiol. 2022.

. 2022 May 5;29(5):777-778.

doi: 10.1093/eurjpc/zwab178.

Author

Gal Tsaban^{1

2}

Affiliations

¹ Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.
² Department of Cardiology, Heart Institute, Rager Av. 101, Beersheba, 84101, Israel.

PMID: 34904162
DOI: 10.1093/eurjpc/zwab178

No abstract available

PubMed Disclaimer

Comment on

Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis.
de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, Zwinderman AH, Hutten BA. de Boer LM, et al. Eur J Prev Cardiol. 2022 May 5;29(5):779-792. doi: 10.1093/eurjpc/zwab171. Eur J Prev Cardiol. 2022. PMID: 34849724

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information